贝达药业股价跌6.06%，东方基金旗下1只基金重仓，持有4万股浮亏损失17.44万元

Group 1 - The core viewpoint of the news is that Beida Pharmaceutical experienced a significant stock decline of 6.06%, with its share price at 67.56 yuan and a total market capitalization of 28.425 billion yuan as of the report date [1] - Beida Pharmaceutical, established on January 7, 2003, and listed on November 7, 2016, primarily engages in the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales [1] - The trading volume for Beida Pharmaceutical was 1.04 billion yuan, with a turnover rate of 0.36% [1] Group 2 - According to data, one fund from Dongfang Fund holds a significant position in Beida Pharmaceutical, specifically the Dongfang Innovation Growth Mixed A fund, which held 40,000 shares, accounting for 3.12% of the fund's net value [2] - The Dongfang Innovation Growth Mixed A fund has a total scale of 65.2701 million yuan and has achieved a year-to-date return of 28.56%, ranking 2374 out of 8175 in its category [2] - The fund manager, Chen Hao, has been in position for 3 years and 52 days, with the fund's best return during his tenure being 18.71% and the worst being -39.86% [2]